We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
351
CALL
Tenet Healthcare
THC
$22B
– –
-1,415
Closed -$7.01M
THC icon
352
Tenet Healthcare
THC
$22B
– –
-80,481
Closed -$4.11M
TXMD icon
353
TherapeuticsMD
TXMD
$24M
– –
-1,665
Closed -$587K
VNDA icon
354
CALL
Vanda Pharmaceuticals
VNDA
$303M
– –
-2,019
Closed -$1.88M
VNDA icon
355
Vanda Pharmaceuticals
VNDA
$303M
– –
-113,165
Closed -$1.05M
VTRS icon
356
Viatris
VTRS
$20.7B
– –
-56,800
Closed -$4.01M
ORKA
357
Oruka Therapeutics
ORKA
$5.3B
– –
-93
Closed -$112K
ITCI
358
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-100,000
Closed -$2.54M
RVNC
359
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-23,065
Closed -$593K
VIRX
360
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-19
Closed -$993K
NBSE
361
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-13
Closed -$1.29M
NBSE
362
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-5
Closed -$498K
EIGR
363
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-5
Closed -$4.52M
SCTL
364
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-27,196
Closed -$221K
ICPT
365
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-843
Closed -$23.8M
ICPT
366
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-66
Closed -$1.86M
ATHX
367
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-14
Closed -$99K
EPZM
368
DELISTED
Epizyme, Inc
EPZM
– –
-111,536
Closed -$2.1M
CERN
369
CALL
DELISTED
Cerner Corp
CERN
– –
-536
Closed -$3.93M
CERN
370
PUT
DELISTED
Cerner Corp
CERN
– –
-499
Closed -$3.66M
HSTO
371
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-1
Closed -$140K
CSLT
372
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-217,600
Closed -$1.81M
IMMU
373
DELISTED
Immunomedics Inc
IMMU
– –
-137,751
Closed -$528K
SCON
374
PUT
DELISTED
Superconductor Technologies Inc.
SCON
– –
0
– -$19K
AGN
375
CALL
DELISTED
Allergan plc
AGN
– –
-1,205
Closed -$35.9M
12 13 14
15
16

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.